{"nctId":"NCT01501513","briefTitle":"A Safety Study of 3 Different Bowel Cleansing Preparations","startDateStruct":{"date":"2011-12"},"conditions":["Colonoscopy","Bowel Preparation","Endoscopy"],"count":541,"armGroups":[{"label":"BLI800 approved preparation regimen","type":"EXPERIMENTAL","interventionNames":["Drug: BLI800 approved preparation regimen"]},{"label":"BLI800 investigational preparation regimen","type":"EXPERIMENTAL","interventionNames":["Drug: BLI800 investigational preparation regimen"]},{"label":"PEG-3350 based bowel preparation","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: PEG-3350 based bowel preparation"]}],"interventions":[{"name":"PEG-3350 based bowel preparation","otherNames":[]},{"name":"BLI800 approved preparation regimen","otherNames":[]},{"name":"BLI800 investigational preparation regimen","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.\n* At least 18 years of age\n* If female, and of child-bearing potential, is using an acceptable form of birth control\n* Negative urine pregnancy test at screening, if applicable\n* In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.\n* Subjects who had previous significant gastrointestinal surgeries.\n* Subjects who have uncontrolled clinically significant pre-existing electrolyte disturbances.\n* Subjects with severe liver or renal insufficiency.\n* Subjects with a history of congestive heart failure or other clinically significant cardiac abnormality.\n* Subjects with impaired consciousness that predisposes them to pulmonary aspiration.\n* Subjects undergoing colonoscopy for foreign body removal and decompression.\n* Subjects who are pregnant or lactating, or intending to become pregnant during the study.\n* Subjects of childbearing potential who refuse a pregnancy test.\n* Subjects allergic to any preparation components\n* Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.\n* Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Successful Bowel Preparation","description":"Successful bowel preparation is defined as a preparation rated as Excellent or Good by the blinded endoscopist on a 4 point scale (Excellent, Good, Fair, Poor).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"132","spread":null},{"groupId":"OG002","value":"137","spread":null}]}]}]},{"type":"SECONDARY","title":"Count and Percentage of Subjects With Adverse Events Through Day of Colonoscopy","description":"Count and Percentage of subjects with AEs through Day of Colonoscopy based on 3% threshold. Outcome measure time frame represents the day prior to colonoscopy (when preparation Dose 1 is taken) and the day of colonoscopy (when preparation Dose 2 is taken).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Count and Percentage of Subjects With Adverse Events After Colonoscopy Through Follow-up Day 7","description":"Count and Percentage of subjects with AEs reported after colonoscopy through follow-up Day 7 based on 3% threshold. Outcome measure time frame represents the period following colonoscopy through follow-up Day 7 (7 days).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":184},"commonTop":["Discomfort","Abdominal distension","Nausea","Abdominal pain","Vomiting"]}}}